Roche received U.S. FDA 510(k) clearance for Cobas lab automation units and also gained CE marking for a multiplex blood donor screening assay. The automation modules (Cobas c 703 and Cobas ISE Neo) are designed to scale clinical chemistry and ISE throughput within the Cobas Pro Integrated Solutions platform. Separately, Roche’s molecular Cobas MPX-E assay earned CE marking for blood donor screening, using multiplex PCR to detect multiple viral targets including HIV-1 and hepatitis viruses in an integrated 4-in-1 workflow. Dual-target detection for HIV-1 group M is intended to maintain sensitivity despite potential mutations. Taken together, the updates focus on throughput and lab workflow resilience—addressing capacity constraints while maintaining screening performance expectations for blood safety.